US Stocks
Gritstone Bio Inc
Gritstone Bio Inc

Gritstone Bio Inc (GRTS)


  • $







Key Stats

Today Low/High$5.68 / $6.15
52 Week Low/High$6 / $35.2
Market Cap$446M

Company Details

Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, as well as a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.
OrganisationGritstone Bio Inc
HeadquatersEmeryville, California, US
IndustryHealth Technology
CEOAndrew Allen

Discover more

Frequently Asked Questions

What is Gritstone Bio Inc (GRTS) share price today?

Can Indians buy Gritstone Bio Inc (GRTS) shares?

How can I buy Gritstone Bio Inc (GRTS) shares from India?

Can Fractional shares of Gritstone Bio Inc (GRTS) be purchased?

What are the documents required to start investing in Gritstone Bio Inc (GRTS) stocks?